Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:DWTXNASDAQ:MBRXNASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.24+1.7%$7.91$6.51▼$13.27$8.74M1.6294,012 shs2,636 shsDWTXDogwood Therapeutics$4.65-10.2%$4.87$1.62▼$29.28$8.89M1.881.63 million shs51,803 shsMBRXMoleculin Biotech$0.64-4.0%$0.90$0.40▼$4.90$9.07M1.561.54 million shs305,713 shsSHPHShuttle Pharmaceuticals$0.13-9.4%$0.24$0.12▼$4.30$1.46M-1.11.81 million shs3.99 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+1.65%-19.41%+2.04%+12.55%-3.01%DWTXDogwood Therapeutics-10.23%-4.91%-4.12%-24.02%+464,999,900.00%MBRXMoleculin Biotech-3.96%-4.18%-35.35%-43.19%-85.14%SHPHShuttle Pharmaceuticals-9.35%-27.59%-43.08%-64.11%+331,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.523 of 5 stars3.55.00.00.02.00.80.0DWTXDogwood Therapeutics2.0114 of 5 stars3.50.00.00.02.00.01.3MBRXMoleculin Biotech3.3465 of 5 stars3.55.00.00.03.30.01.3SHPHShuttle Pharmaceuticals0.8116 of 5 stars0.04.00.00.01.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00263.90% UpsideDWTXDogwood Therapeutics 3.00Buy$10.00115.05% UpsideMBRXMoleculin Biotech 3.00Buy$4.00523.05% UpsideSHPHShuttle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SHPH, ADXN, DWTX, and MBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.004/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.003/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$404.10K21.62N/AN/A$1.20 per share6.87DWTXDogwood TherapeuticsN/AN/AN/AN/A$4.94 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%9/1/2025 (Estimated)DWTXDogwood Therapeutics-$5.30M-$18.04N/AN/AN/AN/A-217.12%-172.06%8/6/2025 (Estimated)MBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%8/4/2025 (Estimated)SHPHShuttle Pharmaceuticals-$6.59M-$4.15N/A∞N/AN/A-583.02%-258.92%N/ALatest SHPH, ADXN, DWTX, and MBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A5/8/2025Q1 2025SHPHShuttle PharmaceuticalsN/A-$7.50N/A-$0.30N/AN/A3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59DWTXDogwood TherapeuticsN/A1.711.71MBRXMoleculin BiotechN/A2.082.08SHPHShuttle PharmaceuticalsN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%DWTXDogwood Therapeutics9.05%MBRXMoleculin Biotech15.52%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%DWTXDogwood Therapeutics3.90%MBRXMoleculin Biotech1.90%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableDWTXDogwood Therapeutics51.91 million1.17 millionN/AMBRXMoleculin Biotech2014.13 million3.86 millionNot OptionableSHPHShuttle Pharmaceuticals510.98 million2.46 millionNot OptionableSHPH, ADXN, DWTX, and MBRX HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals says reverse stock split to become effective June 16June 13 at 3:10 PM | finance.yahoo.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern TimeJune 12 at 12:00 PM | globenewswire.comShuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq RequirementsJune 12 at 8:56 AM | quiverquant.comShuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance InitiativeJune 12 at 8:30 AM | globenewswire.comShuttle Pharma Appoints George Scorsis Chairman of the Board of DirectorsJune 4, 2025 | globenewswire.comShuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cashMay 29, 2025 | bizjournals.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deShuttle Pharma Provides Corporate UpdateMay 15, 2025 | globenewswire.comShuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical TrialMay 8, 2025 | globenewswire.comShuttle Pharmaceuticals to Present Phase 2 Trial Update at Planet MicroCap Showcase: VEGAS 2025April 24, 2025 | nasdaq.comShuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 21, 2025 | globenewswire.comShuttle Pharmaceuticals files provisional patent application with USPTOApril 12, 2025 | markets.businessinsider.comShuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApril 10, 2025 | globenewswire.comShuttle Pharmaceuticals Appoints New Interim CEO and CSOMarch 31, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc. Closes $5.75 Million Public Offering to Fund Phase II Clinical TrialMarch 13, 2025 | quiverquant.comShuttle Pharma Announces Closing of $5.75 Million Underwritten OfferingMarch 13, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business ActivitiesMarch 12, 2025 | finanznachrichten.deShuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEOMarch 12, 2025 | markets.businessinsider.comShuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offeringMarch 12, 2025 | markets.businessinsider.comShuttle Pharma Announces Pricing of $5.75 Million Underwritten OfferingMarch 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHPH, ADXN, DWTX, and MBRX Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.24 +0.13 (+1.65%) Closing price 06/13/2025 03:57 PM EasternExtended Trading$8.24 +0.00 (+0.01%) As of 06/13/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Dogwood Therapeutics NASDAQ:DWTX$4.65 -0.53 (-10.23%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.83 +0.18 (+3.87%) As of 06/13/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Moleculin Biotech NASDAQ:MBRX$0.64 -0.03 (-3.96%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.64 +0.00 (+0.47%) As of 06/13/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Shuttle Pharmaceuticals NASDAQ:SHPH$0.13 -0.01 (-9.35%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.13 0.00 (-1.36%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
